ASX Announcement

EXTENSION OF TIME TO HOLD ANNUAL GENERAL MEETING

7 November 2025, Adelaide, Australia: Mayne Pharma Group Limited (ASX:MYX) (**Mayne Pharma**) refers to its proposed acquisition by Cosette Pharmaceuticals, Inc. (**Cosette**) by way of a scheme of arrangement (**Scheme**) and its announcement earlier today providing an update on the status of FIRB approval and setting out the indicative timetable for implementation of the Scheme.

Mayne Pharma announces that the Australian Securities and Investments Commission (**ASIC**) has formally granted Mayne Pharma an extension of time under section 250P of the Corporations Act 2001 (Cth) for Mayne Pharma to hold its 2025 Annual General Meeting (**AGM**) from on or before 28 November 2025 to on or before 30 January 2026. The extension of time for the AGM was sought by Mayne Pharma to a date beyond the expected date for the implementation of the Scheme (**AGM Extension**).

As a result of the AGM Extension granted by ASIC, if the FIRB condition is satisfied, Court approval is granted and the Scheme is implemented according to the current indicative timetable, Mayne Pharma will not be required to hold or actually hold an AGM for the financial year ended 30 June 2025 as Mayne Pharma will have only one shareholder at that point. Conversely, if Mayne Pharma is required to hold an AGM, the date of the AGM will be announced to the ASX at the appropriate time.

As previously announced, the Scheme remains subject to Court approval and other conditions precedent as set out in the Scheme Booklet (and as outlined in clause 3.1 of the Scheme Implementation Deed). Mayne Pharma will announce any changes to the Scheme timetable to the ASX.

Please contact Dr Tom Duthy (see details below) if you have any questions about the AGM Extension.

- ENDS -

Authorised for release to the ASX by the Board of Directors

For further information contact:

Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.